<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd"><id>2934762</id><setSpec>journal_article</setSpec><setSpec>doc-type:article</setSpec><setSpec>ddc:540</setSpec><setSpec>journal_articleFtxt</setSpec><setSpec>open_access</setSpec>

<genre>article</genre>

<titleInfo><title>Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery</title></titleInfo>


<note type="publicationStatus">published</note>


<note type="qualityControlled">yes</note>

<name type="personal">
  <namePart type="given">Adina Noémi</namePart>
  <namePart type="family">Borbély</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">70994745</identifier></name>
<name type="personal">
  <namePart type="given">Eduard</namePart>
  <namePart type="family">Figueras Agustí</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">70995989</identifier></name>
<name type="personal">
  <namePart type="given">Ana</namePart>
  <namePart type="family">Martins</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Simone</namePart>
  <namePart type="family">Esposito</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Giulio</namePart>
  <namePart type="family">Auciello</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Edith</namePart>
  <namePart type="family">Monteagudo</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Annalise</namePart>
  <namePart type="family">Di Marco</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Vincenzo</namePart>
  <namePart type="family">Summa</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Paola</namePart>
  <namePart type="family">Cordella</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Raffaella</namePart>
  <namePart type="family">Perego</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Isabell</namePart>
  <namePart type="family">Kemker</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">80991621</identifier></name>
<name type="personal">
  <namePart type="given">Marcel</namePart>
  <namePart type="family">Frese</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">34814078</identifier><description xsi:type="identifierDefinition" type="orcid">0000-0002-2232-7755</description></name>
<name type="personal">
  <namePart type="given">Paola</namePart>
  <namePart type="family">Gallinari</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Christian</namePart>
  <namePart type="family">Steinkühler</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Norbert</namePart>
  <namePart type="family">Sewald</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">20281</identifier><description xsi:type="identifierDefinition" type="orcid">0000-0002-0309-2655</description></name>







<name type="corporate">
  <namePart/>
  <identifier type="local">17977</identifier>
  <role>
    <roleTerm type="text">department</roleTerm>
  </role>
</name>








<abstract lang="eng">Cryptophycins are potent tubulin polymerization inhibitors with picomolar antiproliferative potency in vitro and activity against multidrug-resistant (MDR) cancer cells. Because of neurotoxic side effects and limited efficacy in vivo, cryptophycin-52 failed as a clinical candidate in cancer treatment. However, this class of compounds has emerged as attractive payloads for tumor-targeting applications. In this study, cryptophycin was conjugated to the cyclopeptide c(RGDfK), targeting integrin αvβ3, across the protease-cleavable Val-Cit linker and two different self-immolative spacers. Plasma metabolic stability studies in vitro showed that our selected payload displays an improved stability compared to the parent compound, while the stability of the conjugates is strongly influenced by the self-immolative moiety. Cathepsin B cleavage assays revealed that modifications in the linker lead to different drug release profiles. Antiproliferative effects of Arg-Gly-Asp (RGD)–cryptophycin conjugates were evaluated on M21 and M21-L human melanoma cell lines. The low nanomolar in vitro activity of the novel conjugates was associated with inferior selectivity for cell lines with different integrin αvβ3 expression levels. To elucidate the drug delivery process, cryptophycin was replaced by an infrared dye and the obtained conjugates were studied by confocal microscopy</abstract>

<relatedItem type="constituent">
  <location>
    <url displayLabel="pharmaceutics-11-00151.sewald.pdf">https://pub.uni-bielefeld.de/download/2934762/2934767/pharmaceutics-11-00151.sewald.pdf</url>
  </location>
  <physicalDescription><internetMediaType>application/pdf</internetMediaType></physicalDescription>
  <accessCondition type="restrictionOnAccess">no</accessCondition>
</relatedItem>
<originInfo><publisher>MDPI AG</publisher><dateIssued encoding="w3cdtf">2019</dateIssued>
</originInfo>
<language><languageTerm authority="iso639-2b" type="code">eng</languageTerm>
</language>

<subject><topic>antitumor agents</topic><topic>small molecule–drug conjugates</topic><topic>drug delivery</topic><topic>RGD peptides</topic>
</subject>


<relatedItem type="host"><titleInfo><title>Pharmaceutics</title></titleInfo>
  <identifier type="issn">1999-4923</identifier>
  <identifier type="eIssn">1999-4923</identifier>
  <identifier type="MEDLINE">30939768</identifier>
  <identifier type="ISI">000467301400006</identifier><identifier type="urn">urn:nbn:de:0070-pub-29347627</identifier><identifier type="doi">10.3390/pharmaceutics11040151</identifier>
<part><detail type="volume"><number>11</number></detail><detail type="issue"><number>4</number></detail>
</part>
</relatedItem>
<relatedItem type="Supplementary material">
  <location>     <url>https://pub.uni-bielefeld.de/record/2937966</url>  </location>
</relatedItem>

<extension>
<bibliographicCitation>
<chicago>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Borbély, Adina Noémi, Figueras Agustí, Eduard, Martins, Ana, Esposito, Simone, Auciello, Giulio, Monteagudo, Edith, Di Marco, Annalise, et al. 2019. “Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery”. &lt;em&gt;Pharmaceutics&lt;/em&gt; 11 (4): 151.&lt;/div&gt;</chicago>
<lncs> Borbély, A.N., Figueras Agustí, E., Martins, A., Esposito, S., Auciello, G., Monteagudo, E., Di Marco, A., Summa, V., Cordella, P., Perego, R., Kemker, I., Frese, M., Gallinari, P., Steinkühler, C., Sewald, N.: Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. Pharmaceutics. 11, : 151 (2019).</lncs>
<ama>Borbély AN, Figueras Agustí E, Martins A, et al. Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. &lt;em&gt;Pharmaceutics&lt;/em&gt;. 2019;11(4): 151.</ama>
<bio1>Borbély AN, Figueras Agustí E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, Frese M, Gallinari P, Steinkühler C, Sewald N (2019) &lt;br /&gt;Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery.&lt;br /&gt;Pharmaceutics 11(4): 151.</bio1>
<angewandte-chemie>A. N.  Borbély, E.  Figueras Agustí, A.  Martins, S.  Esposito, G.  Auciello, E.  Monteagudo, A.  Di Marco, V.  Summa, P.  Cordella, R.  Perego, et al., “Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery”, &lt;em&gt;Pharmaceutics&lt;/em&gt;, &lt;strong&gt;2019&lt;/strong&gt;, &lt;em&gt;11&lt;/em&gt;, : 151.</angewandte-chemie>
<dgps>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Borbély, A.N., Figueras Agustí, E., Martins, A., Esposito, S., Auciello, G., Monteagudo, E., Di Marco, A., Summa, V., Cordella, P., Perego, R., Kemker, I., Frese, M., Gallinari, P., Steinkühler, C. &amp;amp; Sewald, N. (2019). Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. &lt;em&gt;Pharmaceutics&lt;/em&gt;, &lt;em&gt;11&lt;/em&gt;(4): 151. MDPI AG. doi:10.3390/pharmaceutics11040151.&lt;/div&gt;</dgps>
<apa>Borbély, A. N., Figueras Agustí, E., Martins, A., Esposito, S., Auciello, G., Monteagudo, E., Di Marco, A., et al. (2019). Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. &lt;em&gt;Pharmaceutics&lt;/em&gt;, &lt;em&gt;11&lt;/em&gt;(4), 151. doi:10.3390/pharmaceutics11040151</apa>
<ieee> A.N. Borbély, et al., “Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery”, &lt;em&gt;Pharmaceutics&lt;/em&gt;,  vol. 11, 2019, : 151.</ieee>
<harvard1>Borbély, A.N., et al., 2019. Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. &lt;em&gt;Pharmaceutics&lt;/em&gt;, 11(4): 151.</harvard1>
<default>Borbély AN, Figueras Agustí E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, et al. (2019) &lt;br /&gt;&lt;em&gt;Pharmaceutics&lt;/em&gt; 11(4): 151.</default>
<mla>Borbély, Adina Noémi, Figueras Agustí, Eduard, Martins, Ana, Esposito, Simone, Auciello, Giulio, Monteagudo, Edith, Di Marco, Annalise, Summa, Vincenzo, Cordella, Paola, Perego, Raffaella, Kemker, Isabell, Frese, Marcel, Gallinari, Paola, Steinkühler, Christian, and Sewald, Norbert. “Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery”. &lt;em&gt;Pharmaceutics&lt;/em&gt; 11.4 (2019): 151.</mla>
<apa_indent>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Borbély, A. N., Figueras Agustí, E., Martins, A., Esposito, S., Auciello, G., Monteagudo, E., Di Marco, A., et al. (2019). Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. &lt;em&gt;Pharmaceutics&lt;/em&gt;, &lt;em&gt;11&lt;/em&gt;(4), 151. doi:10.3390/pharmaceutics11040151&lt;/div&gt;</apa_indent>
<frontiers>Borbély, A. N., Figueras Agustí, E., Martins, A., Esposito, S., Auciello, G., Monteagudo, E., Di Marco, A., Summa, V., Cordella, P., Perego, R., et al. (2019). Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. &lt;em&gt;Pharmaceutics&lt;/em&gt; 11:151.</frontiers>
<wels>Borbély, A. N.; Figueras Agustí, E.; Martins, A.; Esposito, S.; Auciello, G.; Monteagudo, E.; Di Marco, A.; Summa, V.; Cordella, P.; Perego, R.; Kemker, I.; Frese, M.; Gallinari, P.; Steinkühler, C.; Sewald, N. (2019): Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery &lt;em&gt;Pharmaceutics&lt;/em&gt;,11:(4):151</wels>
</bibliographicCitation>
</extension>
<recordInfo><recordIdentifier>2934762</recordIdentifier><recordCreationDate encoding="w3cdtf">2019-04-04T09:43:42Z</recordCreationDate><recordChangeDate encoding="w3cdtf">2020-03-20T12:47:22Z</recordChangeDate>
</recordInfo>
</mods>